NCT07428018 2026-03-05
VIOLET
Mario Negri Institute for Pharmacological Research
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07410559 2026-02-18
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07340541 2026-02-09
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07292207 2025-12-18
ARCHE
Nagoya City University
Phase 2 Not yet recruiting
NCT07191717 2025-11-10
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06810492 2025-03-17
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Phase NA Not yet recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06561022 2024-08-19
abemaSNF1/3
Fudan University
Phase 2 Not yet recruiting
NCT06341283 2024-05-10
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
The Affiliated Hospital of Qingdao University
Not yet recruiting